| Literature DB >> 24212601 |
Masato Hasegawa1, Sayuri Watanabe, Hiromi Kondo, Haruhiko Akiyama, David M A Mann, Yuko Saito, Shigeo Murayama.
Abstract
Entities:
Mesh:
Substances:
Year: 2013 PMID: 24212601 PMCID: PMC3895182 DOI: 10.1007/s00401-013-1191-9
Source DB: PubMed Journal: Acta Neuropathol ISSN: 0001-6322 Impact factor: 17.088
Fig. 1a–f Immunostaining of AD sections after Ac and FA treatment before (a, c, e) and after (b, d, f) Pro-K treatment, using RD3 (a, b), RD4 (c, d) and anti-4R (e, f). Bar 100 μm. g–j Immunoblots of Sarkosyl-insoluble tau from two AD brains, before (Con) and after treatments with trypsin or Pro-K, using RD3 (g), RD4 (h), anti-4R (i) and pS396 (j). k–l Computed cross-section through a paired helical filament (k) [reproduced from Ref. [1], with permission of the publisher], a predicted folding model of 3R and 4R tau in PHF (l). RD3 and RD4 epitopes are indicated by blue and red, respectively. 4R tau specific insertion is indicated by underlining. The deamidation site N279 is indicated by asterisks. Phosphorylation of Ser396 is indicated. Possible trypsin, pronase and Pro-K cleavage sites are indicated in green, purple and dark blue arrows, respectively. The protease-resistant domain of PHF is indicated as PHF-core